Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Science and Technology Meeting of the Faculty of Pharmaceutical Sciences, University of São Paulo. Unidades: FCF, ICB
Subjects: MYCOBACTERIUM TUBERCULOSIS, INIBIDORES DE ENZIMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Alfredo Danilo Ferreira de et al. Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 29 maio 2024. , 2018APA
Souza, A. D. F. de, Ribeiro, J. A., Ribeiro, G. M., Trossini, G. H. G., Dias, M. V. B., & Parise Filho, R. (2018). Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Souza ADF de, Ribeiro JA, Ribeiro GM, Trossini GHG, Dias MVB, Parise Filho R. Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity. Brazilian Journal of Pharmaceutical Sciences. 2018 ; 54 39 res. FCF073.[citado 2024 maio 29 ]Vancouver
Souza ADF de, Ribeiro JA, Ribeiro GM, Trossini GHG, Dias MVB, Parise Filho R. Optimization of new dihydrofolate reductase inhibitors of mycobacterium tuberculosis (mtDHFR): molecular docking, synthesis, evaluation of enzyme inhibition and antimycobacterial activity. Brazilian Journal of Pharmaceutical Sciences. 2018 ; 54 39 res. FCF073.[citado 2024 maio 29 ]